arginyl-glycyl-aspartic acid and pd 0325901

arginyl-glycyl-aspartic acid has been researched along with pd 0325901 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, Z; He, H; Hou, J; Li, X; Liu, X; Wang, C; Wu, Y; Xu, P; Yang, Z; Zhang, L	1
Chen, Z; Diao, Y; Hou, J; Li, W; Wu, Y; Yang, Z; Zhang, L	1

Other Studies

2 other study(ies) available for arginyl-glycyl-aspartic acid and pd 0325901

Article	Year
Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy. Molecules (Basel, Switzerland), 2013, Nov-12, Volume: 18, Issue:11 Topics: Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Flow Cytometry; Humans; Integrin alphaVbeta3; Integrins; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Oligopeptides; Protein Kinase Inhibitors	2013
RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy. International journal of pharmaceutics, 2016, May-30, Volume: 505, Issue:1-2 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Central Nervous System Neoplasms; Diphenylamine; Drug Delivery Systems; Drug Liberation; Drug Synergism; Female; Glioblastoma; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Oligopeptides; Xenograft Model Antitumor Assays	2016

Article

Year

Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy.

Molecules (Basel, Switzerland), 2013, Nov-12, Volume: 18, Issue:11

Topics: Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Flow Cytometry; Humans; Integrin alphaVbeta3; Integrins; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Oligopeptides; Protein Kinase Inhibitors

2013

RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy.

International journal of pharmaceutics, 2016, May-30, Volume: 505, Issue:1-2

Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Central Nervous System Neoplasms; Diphenylamine; Drug Delivery Systems; Drug Liberation; Drug Synergism; Female; Glioblastoma; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Oligopeptides; Xenograft Model Antitumor Assays

2016